June 13, 2022
Latham & Watkins has advised Peptone, a molecular computational physics company focused on protein drug discovery, on its US$40 million Series A financing round. Peptone’s technology combines computational molecular physics and neural networks to analyse the behaviour and structure of proteins. It is used in a variety of pre-clinical and late-stage protein therapeutics programs. The fundraising will be used to develop the world’s most advanced facility dedicated to solving complex and problematic intrinsically disordered protein structures at scale, pioneering a new class of potential therapeutic targets and drugs.
The round was led by F-Prime Capital and Bessemer Venture Partners, with participation from Walden Catalyst Ventures and existing investors, including Hoxton Ventures and dRX Capital, the venture arm of Novartis.
The Latham team was led by London corporate partner Shing Lo, with associate Aaron Bassett.